Skip to main content
Move the World.
psychedelic medicine

Lead Image Courtesy of NYU Langone Health

Another august institution is throwing its weight behind the psychedelic research renaissance: NYU is launching a Center for Psychedelic Medicine.

Established with $10 million in funding, the Center for Psychedelic Medicine — under the direction of Michael Bogenschutz, professor of psychiatry at NYU Grossman School of Medicine — will "support health-focused research across the translational spectrum," as the university release puts it, from basic science to phase 3 clinical trials.

NYU joins a quickly crowding field, as centers dedicated to psychedelic medicine and research have recently opened their doors — and opened minds — at Johns Hopkins and Mount Sinai

But NYU Langone, in New York City, is no stranger to the field; previous studies out of NYU have examined using psychedelics to treat distress in patients with cancer, addiction, and PTSD, as well as research on more exotic drugs, like ibogaine.

Psychedelic medicine startup MindMed is providing the lion's share of the funding, kicking in $5 million. The company — which is developing psychedelic medicines — was founded by J.R. Rahn, who came to psychedelic medicine, as so many others do, from a place of deep need.

"To the outside world, I was doing really well, but inside me I was struggling," Rahn told the New Yorker's Nathan Heller. He turned to a bottle of wine to sleep, cocaine to party, benzodiazepines for his anxiety.

"A friend recommended I have a psychedelic experience, to piece together a solution," he told Heller. He tried psilocybin and LSD, which helped him to process his traumatic memories of discovering the body of his mother, who died during a vacation in the Dominican Republic when Rahn was eight.

MindMed's contribution is earmarked for funding the Center's Psychedelic Medicine Research Training Program, which NYU believes is a differentiator from the other research centers forming psychedelics' academic ecosystem.

That program is designed to develop postdocs and early career faculty members into independent psychedelic medicine researchers.

"This is a new era in psychopharmacology," Yale professor of psychiatry and neuroscience John Krystal — whose lab pioneered the medicinal use of ketamine as a treatment for depression — told me via email.

"With the approval of esketamine by the FDA for the treatment of patients with treatment-resistant forms of depression and depression in the context of high suicide risk, we have the need for a new type of expert psychopharmacologist."

Established with $10 million in funding, the center will "support health-focused research across the translational spectrum," as NYU puts it.

The kind the Center for Psychedelic Medicine's program is looking to train. The Psychedelic Medicine Research Training Program will provide clinical investigators with training and salary support, as well as funding four research positions.

"These initiatives will provide an environment in which scientists, clinicians, trainees, and other staff contribute in meaningful ways to ensure that the momentum created by the modern psychedelic renaissance is sustained and continues to yield medical breakthroughs backed by sound science," Bogenschutz said in the release.

We'd love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected]

Up Next

Dope Science
Take a Trip to Johns Hopkins' New Psychedelic Research Center
Take a Trip to Johns Hopkins' New Psychedelic Research Center
Dope Science
Take a Trip to Johns Hopkins' New Psychedelic Research Center
Johns Hopkins is throwing its considerable clout behind the fast-growing field of psychedelic research, pouring $17 million into a research center to study the hallucinogenic drugs.

Johns Hopkins is throwing its considerable clout behind the fast-growing field of psychedelic research, pouring $17 million into a research center to study the hallucinogenic drugs.

Dope Science
MDMA Therapy and the Promise of Psychedelics
mdma therapy
Dope Science
MDMA Therapy and the Promise of Psychedelics
Despite years of work with a "stellar" therapist, Charlotte needed more. She turned to MDMA therapy.

Despite years of work with a "stellar" therapist, Charlotte needed more. She turned to MDMA therapy.

Drugs
Smart Vape Pen Claims to Solve the Cannabis Dosing Problem
cannabis dosing smart vape pen
Drugs
Smart Vape Pen Claims to Solve the Cannabis Dosing Problem
To solve the cannabis dosing problem, the MODE smart vape vibrates when a person should stop inhaling and again when they should exhale.

To solve the cannabis dosing problem, the MODE smart vape vibrates when a person should stop inhaling and again when they should exhale.

Dope Science
Microdosing Mushrooms: Explained
microdosing mushrooms
Dope Science
Microdosing Mushrooms: Explained
Microdosing mushrooms — taking doses of psilocybin too small to cause a trip to enhance daily life — is gaining momentum. But does science support it?

Microdosing mushrooms — taking doses of psilocybin too small to cause a trip to enhance daily life — is gaining momentum. But does science support it?

Dope Science
Psilocybin Therapy Appears to Dramatically Reduce Depression
Psilocybin Therapy
Dope Science
Psilocybin Therapy Appears to Dramatically Reduce Depression
Psilocybin therapy — a combination of traditional therapy and supervised “trips” on the magic mushroom compound — shows promise as a depression treatment.

Psilocybin therapy — a combination of traditional therapy and supervised “trips” on the magic mushroom compound — shows promise as a depression treatment.

Dope Science
“Candy Flipping” — Mixing MDMA and LSD — Is Hitting the Lab
candy-flipping
Dope Science
“Candy Flipping” — Mixing MDMA and LSD — Is Hitting the Lab
A clinical trial of mixing LSD and MDMA, known as “candy flipping,” wants to see if molly can take a trip’s edge off and make LSD therapy more effective.

A clinical trial of mixing LSD and MDMA, known as “candy flipping,” wants to see if molly can take a trip’s edge off and make LSD therapy more effective.

Dope Science
Microdosing LSD May Provide Pain Relief
microdosing lsd
Dope Science
Microdosing LSD May Provide Pain Relief
Since the 1960s, LSD has been seen as a potential painkiller. Now, new research suggests microdosing LSD may indeed provide relief.

Since the 1960s, LSD has been seen as a potential painkiller. Now, new research suggests microdosing LSD may indeed provide relief.

Dope Science
Psilocybin May Impact Your Ego Center
psilocybin
Dope Science
Psilocybin May Impact Your Ego Center
You’ve heard about “ego death” on magic mushrooms. New research suggests psilocybin curbs part of the brain that may tie in to ego.

You’ve heard about “ego death” on magic mushrooms. New research suggests psilocybin curbs part of the brain that may tie in to ego.

Dope Science
An LSD Trip “Off-Switch” May Be Coming Soon
LSD Trip
Dope Science
An LSD Trip “Off-Switch” May Be Coming Soon
Pharmaceutical startup MindMed is developing tech it believes could serve as an “off switch” for an LSD trip during therapy sessions.

Pharmaceutical startup MindMed is developing tech it believes could serve as an “off switch” for an LSD trip during therapy sessions.